Skip to main content
NCBI home page
Annals of Surgery logoLink to Annals of Surgery
. 1987 Dec;206(6):685–693. doi: 10.1097/00000658-198712000-00001

A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases.

A E Chang 1, P D Schneider 1, P H Sugarbaker 1, C Simpson 1, M Culnane 1, S M Steinberg 1
PMCID: PMC1493315  PMID: 2961314

Abstract

Sixty-four patients were entered into a randomized trial that evaluated intra-arterial (I.A.) versus intravenous (I.V.) 5-fluorodeoxyuridine (FUDR) for colorectal liver metastases. There was a significant improved response rate for I.A. (62%) compared with I.V. (17%) treatment (p less than 0.003). However, the improved response rate for patients in whom I.A. therapy was used did not translate to a significantly improved survival rate. The 2-year actuarial survival rates for the groups for which I.A. and I.V. therapy was used were 22% and 15% respectively, with the survival curves not differing significantly (p = 0.27). These results may have been due to the inclusion of patients with tumor in draining hepatic lymph nodes. The presence of tumor in hepatic lymph nodes was associated with a poorer prognosis. Analysis of a subgroup of patients with negative hepatic lymph nodes suggested an improved actuarial survival rate in patients for whom I.A. versus I.V. therapy was used (p less than 0.03). The toxicity of I.A. FUDR was considerable, and side effects included chemical hepatitis (79%), biliary sclerosis (21%), peptic ulcers (17%), and gastritis/duodenitis (21%). The only major effect of toxicity of I.V. FUDR was severe diarrhea (59%). Regional I.A. FUDR allowed more drug delivery to liver tumors, which resulted in increased tumor responses when compared with use of systemic therapy. However, the small gain in survival seen in a select subgroup of patients with negative hepatic nodes appeared to be offset by the toxicity of I.A. FUDR.

Full text

PDF
685

Images in this article

688Figs. 1A-D.
on p.688

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. August D. A., Sugarbaker P. H., Schneider P. D. Lymphatic dissemination of hepatic metastases. Implications for the follow-up and treatment of patients with colorectal cancer. Cancer. 1985 Apr 1;55(7):1490–1494. doi: 10.1002/1097-0142(19850401)55:7<1490::aid-cncr2820550712>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  2. BREEDIS C., YOUNG G. The blood supply of neoplasms in the liver. Am J Pathol. 1954 Sep-Oct;30(5):969–977. [PMC free article] [PubMed] [Google Scholar]
  3. Balch C. M., Urist M. M., Soong S. J., McGregor M. A prospective phase II clinical trial of continuous FUDR regional chemotherapy for colorectal metastases to the liver using a totally implantable drug infusion pump. Ann Surg. 1983 Nov;198(5):567–573. doi: 10.1097/00000658-198311000-00001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barone R. M., Byfield J. E., Goldfarb P. B., Frankel S., Ginn C., Greer S. Intra-arterial chemotherapy using an implantable infusion pump and liver irradiation for the treatment of hepatic metastases. Cancer. 1982 Sep 1;50(5):850–862. doi: 10.1002/1097-0142(19820901)50:5<850::aid-cncr2820500508>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  5. Blackshear P. J., Dorman F. D., Blackshear P. L., Jr, Varco R. L., Buchwald H. The design and initial testing of an implantable infusion pump. Surg Gynecol Obstet. 1972 Jan;134(1):51–56. [PubMed] [Google Scholar]
  6. Buchwald H., Grage T. B., Vassilopoulos P. P., Rohde T. D., Varco R. L., Blackshear P. J. Intraarterial infusion chemotherapy for hepatic carcinoma using a totally implantable infusion pump. Cancer. 1980 Mar 1;45(5):866–869. doi: 10.1002/1097-0142(19800301)45:5<866::aid-cncr2820450507>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  7. Cohen A. M., Kaufman S. D., Wood W. C., Greenfield A. J. Regional hepatic chemotherapy using an implantable drug infusion pump. Am J Surg. 1983 Apr;145(4):529–533. doi: 10.1016/0002-9610(83)90053-3. [DOI] [PubMed] [Google Scholar]
  8. Collins J. M. Pharmacologic rationale for regional drug delivery. J Clin Oncol. 1984 May;2(5):498–504. doi: 10.1200/JCO.1984.2.5.498. [DOI] [PubMed] [Google Scholar]
  9. Ensminger W. D., Rosowsky A., Raso V., Levin D. C., Glode M., Come S., Steele G., Frei E., 3rd A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil. Cancer Res. 1978 Nov;38(11 Pt 1):3784–3792. [PubMed] [Google Scholar]
  10. Fortner J. G., Silva J. S., Cox E. B., Golbey R. B., Gallowitz H., Maclean B. J. Multivariate analysis of a personal series of 247 patients with liver metastases from colorectal cancer. II. Treatment by intrahepatic chemotherapy. Ann Surg. 1984 Mar;199(3):317–324. doi: 10.1097/00000658-198403000-00011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Grage T. B., Vassilopoulos P. P., Shingleton W. W., Jubert A. V., Elias E. G., Aust J. B., Moss S. E. Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil versus intravenous 5-fluorouracil in patients with hepatic metastases from colorectal cancer: A Central Oncology Group study. Surgery. 1979 Oct;86(4):550–555. [PubMed] [Google Scholar]
  12. Hohn D., Melnick J., Stagg R., Altman D., Friedman M., Ignoffo R., Ferrell L., Lewis B. Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. J Clin Oncol. 1985 Jan;3(1):98–102. doi: 10.1200/JCO.1985.3.1.98. [DOI] [PubMed] [Google Scholar]
  13. Kemeny M. M., Battifora H., Blayney D. W., Cecchi G., Goldberg D. A., Leong L. A., Margolin K. A., Terz J. J. Sclerosing cholangitis after continuous hepatic artery infusion of FUDR. Ann Surg. 1985 Aug;202(2):176–181. doi: 10.1097/00000658-198508000-00007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kemeny N., Daly J., Oderman P., Shike M., Chun H., Petroni G., Geller N. Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma. J Clin Oncol. 1984 Jun;2(6):595–600. doi: 10.1200/JCO.1984.2.6.595. [DOI] [PubMed] [Google Scholar]
  15. Kemeny N., Daly J. Preliminary results of a randomized study of intrahepatic infusion versus systemic infusion of 5-fluoro-2'-deoxyuridine for metastatic colorectal carcinoma. Recent Results Cancer Res. 1986;100:171–178. doi: 10.1007/978-3-642-82635-1_22. [DOI] [PubMed] [Google Scholar]
  16. Kinsella T. J., Russo A., Mitchell J. B., Collins J. M., Rowland J., Wright D., Glatstein E. A phase I study of intravenous iododeoxyuridine as a clinical radiosensitizer. Int J Radiat Oncol Biol Phys. 1985 Nov;11(11):1941–1946. doi: 10.1016/0360-3016(85)90275-5. [DOI] [PubMed] [Google Scholar]
  17. Lee Y. T. Regional management of liver metastases. I. Cancer Invest. 1983;1(3):237–257. doi: 10.3109/07357908309041363. [DOI] [PubMed] [Google Scholar]
  18. Lien W. M., Ackerman N. B. The blood supply of experimental liver metastases. II. A microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber. Surgery. 1970 Aug;68(2):334–340. [PubMed] [Google Scholar]
  19. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  20. Niederhuber J. E., Ensminger W. D. Surgical considerations in the management of hepatic neoplasia. Semin Oncol. 1983 Jun;10(2):135–147. [PubMed] [Google Scholar]
  21. Niederhuber J. E., Ensminger W., Gyves J., Thrall J., Walker S., Cozzi E. Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer. 1984 Mar 15;53(6):1336–1343. doi: 10.1002/1097-0142(19840315)53:6<1336::aid-cncr2820530620>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  22. Patt Y. Z., Boddie A. W., Jr, Charnsangavej C., Ajani J. A., Wallace S., Soski M., Claghorn L., Mavligit G. M. Hepatic arterial infusion with floxuridine and cisplatin: overriding importance of antitumor effect versus degree of tumor burden as determinants of survival among patients with colorectal cancer. J Clin Oncol. 1986 Sep;4(9):1356–1364. doi: 10.1200/JCO.1986.4.9.1356. [DOI] [PubMed] [Google Scholar]
  23. SULLIVAN R. D., NORCROSS J. W., WATKINS E., Jr CHEMOTHERAPY OF METASTATIC LIVER CANCER BY PROLONGED HEPATIC-ARTERY INFUSION. N Engl J Med. 1964 Feb 13;270:321–327. doi: 10.1056/NEJM196402132700701. [DOI] [PubMed] [Google Scholar]
  24. Shepard K. V., Levin B., Karl R. C., Faintuch J., DuBrow R. A., Hagle M., Cooper R. M., Beschorner J., Stablein D. Therapy for metastatic colorectal cancer with hepatic artery infusion chemotherapy using a subcutaneous implanted pump. J Clin Oncol. 1985 Feb;3(2):161–169. doi: 10.1200/JCO.1985.3.2.161. [DOI] [PubMed] [Google Scholar]
  25. Sugarbaker P. H., Gianola F. J., Dwyer A., Neuman N. R. A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results. Surgery. 1987 Jul;102(1):79–87. [PubMed] [Google Scholar]
  26. Weiss G. R., Garnick M. B., Osteen R. T., Steele G. D., Jr, Wilson R. E., Schade D., Kaplan W. D., Boxt L. M., Kandarpa K., Mayer R. J. Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump. J Clin Oncol. 1983 May;1(5):337–344. doi: 10.1200/JCO.1983.1.5.337. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES